Overall, our findings indicate the prevalence and impact of new ABL1 KD mutations in BCR::ABL1‐positive ALL patients, highlighting the necessity for effective therapies targetingthese mutations. This evidence concerns the gene BCR and acute lymphoblastic leukemia.